Evidence map›Paper›PMID 41632726›Full record

ArticleHormone research in paediatrics2026

Long-Acting PEGylated Growth Hormone in Children with Idiopathic Short Stature: 2-Year Results.

Ling Hou, Yu Yang, Sha Zhao, Guanping Dong, Linqi Chen, Pin Li, Yaping Ma, Chunxiu Gong, Feihong Luo, Xu Xu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ling HouDepartment of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yu YangDepartment of Endocrinology, Genetics, and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang, China.
Sha ZhaoChildren's Health Center, Hunan Children's Hospital, Changsha, China.
Guanping DongDepartment of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Linqi ChenDepartment of Endocrinology, Genetics and Metabolism, Children's Hospital Affiliated to Soochow University, Suzhou, China.
Pin LiDepartment of Medical Genetics and Endocrinology, Children's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Hospital, Shanghai, China.
Yaping MaDepartment of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, China.
Chunxiu GongDepartment of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, China.
Feihong LuoDepartment of Pediatric Endocrinology and Inborn Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China.
Xu XuDepartment of Pediatric Endocrinology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, China.
Haihong GongDepartment of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hongwei DuDepartment of Pediatric Endocrinology, The First Hospital of Jilin University, Changchun, China.
Qiao ShiDepartment of Endocrinology, Genetics, and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang, China.
Yan ZhongChildren's Health Center, Hunan Children's Hospital, Changsha, China.
Xuefeng ChenDepartment of Endocrinology, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Xiuli ChenDepartment of Endocrinology, Genetics and Metabolism, Children's Hospital Affiliated to Soochow University, Suzhou, China.
Liya XuDepartment of Medical Genetics and Endocrinology, Children's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Hospital, Shanghai, China.
Jinling ZhaoDepartment of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, China.
Chang SuDepartment of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, China.
Ruoqian ChengDepartment of Pediatric Endocrinology and Inborn Metabolic Diseases, Children's Hospital of Fudan University, Shanghai, China.
Lulian XuDepartment of Pediatric Endocrinology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, China.
Lina ZhangDepartment of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoping LuoDepartment of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, xpluo@tjh.tjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIdiopathic short stature (ISS) is characterized by short stature without identifiable underlying disorders. Long-acting PEGylated recombinant human growth hormone (PEG-rhGH) has emerged as a promising treatment option for ISS children. The objective of this study was to evaluate the long-term efficacy and safety of weekly PEG-rhGH in ISS children.

methodsThis multicenter, open-label, uncontrolled extension study (extension phase) followed the initial 52-week trial (main phase). All subjects received once-weekly PEG-rhGH at 0.2 mg/kg/week with dose adjustment (up to 0.4 mg/kg/week) based on height velocity (HV) and insulin-like growth factor-1 (IGF-1) standard deviation score (SDS). The primary endpoint was change in height SDS (ΔHT SDS) from baseline; secondary endpoints mainly included HV, changes in bone age/chronological age ratio, IGF-1 SDS, and average annual prescribed dose. Safety was evaluated through adverse events and clinical findings.

resultsOf 280 children enrolled in extension study, 268 completed 52-week treatment. This analysis included results up to week 104, representing 52-week extension phase following the 52-week main phase. At week 104, the least squares means of ΔHT SDS were 1.52, 1.24, and 1.07 for PEG-rhGH 0.2/0.2 mg/kg/week, 0.1/0.2 mg/kg/week, and 0/0.2 mg/kg/week groups, respectively. The 0.2/0.2 mg/kg/week group maintained significantly greater height improvements. HV was highest in the 0/0.2 mg/kg/week group (9.16 ± 1.33 cm/year), reflecting typical first-year catch-up growth. Mean IGF-1 SDS remained within 2SDS during 2 years.

conclusionOnce-weekly PEG-rhGH in children with ISS showed sustained efficacy over 2 years in all assessed height-based outcomes. Treatment remained safe and well tolerated with no new safety signals.

Indexed as

EfficacyIdiopathic short statureLong-acting growth hormonePEGylated recombinant human growth hormoneSafety

Identifiers

PMID41632726
PMCPMC12978803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.